Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22040078 | 0.83 | TRPV1 (0.54) | TRPV1NAMPTMLYCD | |
| SCHEMBL16738817 | 0.81 | TRPV1 (0.53) | TRPV1NAMPTMAPK14 | |
| SCHEMBL23116863 | 0.80 | GFER (0.53) | ACACBNAMPTMAPK14ULK1MLYCD | |
| SCHEMBL12188582 | 0.80 | EPHX2 (0.50) | ACACBNAMPTMAPK14MLYCDCA2 | |
| SCHEMBL4187911 | 0.80 | CES2 (0.55) | TRPV1MAPK14MLYCD | |
| SCHEMBL25231901 | 0.80 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL1147585 | 0.79 | NAMPT (0.46) | ACACBNAMPTMAPK14ULK1MLYCD | |
| SCHEMBL21198695 | 0.79 | OGG1 (0.55) | ACACBCA2 | |
| SCHEMBL3895572 | 0.79 | SMN1; SMN2 (0.58) | — | |
| SCHEMBL15427269 | 0.79 | TRPV1 (0.51) | TRPV1ACACBNAMPTMAPK14ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024201308-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | 주식회사 엘지화학 | 2024-10-03 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2563125-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | CASH BRANDON (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011137022-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040933-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | TRPV1 4121/4885MGLL 4530/4885ACACB 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.